Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Hemera Biosciences LLC logo — Developing HMR59, an intravitreal gene therapy, to preserve...

Hemera Biosciences LLC

Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration.

Founded 2010 United States Waltham, United States 1 employees Series Unknown Total: $1.30M Biotechnology

General Information

Company Name Hemera Biosciences LLC
Founded Year 2010
Location United States Waltham, United States +1
Employees 1
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when Hemera Biosciences LLC moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Hemera Biosciences LLC

Hemera Biosciences LLC is a biotechnology startup based in the United States, founded in 2010. The company is focused on developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration (AMD). Their slogan succinctly captures their mission: "Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration." As a clinical stage gene therapy company, Hemera is driven by the frustration experienced by physicians and scientists in their inability to provide treatment for patients with macular degeneration. Their solution is the gene therapy HMR59, which is currently undergoing FDA clinical trial testing as a one-time treatment for both the dry and wet forms of AMD. Notably, the therapy is administered during a routine office visit with the goal of preserving vision that will endure the life of the patients. The company's last recorded investment was a $1.30M Venture Round investment on 01 April 2013. The investors associated with this round are not specified in the available information. As venture capital analysts, it's important to consider the potential of Hemera Biosciences LLC in addressing a significant unmet medical need and the progress of their clinical trials in evaluating the attractiveness of their investment opportunity.

Taxonomy: gene therapy, clinical stage, AMD treatment, injection therapy, FDA clinical trial, macular degeneration, age-related diseases, vision preservation, complement gene therapy, ophthalmology, clinical research, biopharmaceuticals, recombinant molecules, eye diseases

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 01 Apr 2013

Hemera Biosciences LLC Alternatives & Competitors

Hemera Biosciences LLC vs
Beacon Therapeutics
Beacon Therapeutics United Kingdom

Transforming Vision, Transforming Lives

Series C
95 employees
Biotechnology, Health Care
Hemera Biosciences LLC vs
Adverum Biotechnologies
Adverum Biotechnologies United States

We are on a global mission to establish gene therapy as a new standard of care for the leading cause...

Acquired
133 employees
Biotechnology, Health and Wellness
Hemera Biosciences LLC vs
Catalyst Biosciences
Catalyst Biosciences United States

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unme...

Post Ipo Equity
12 employees
Biopharma, Biotechnology

FAQ About Hemera Biosciences LLC

Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration.
Hemera Biosciences LLC was founded in 2010.
Hemera Biosciences LLC is headquartered in Waltham, United States.
Hemera Biosciences LLC operates in the following industries: Biotechnology.
Hemera Biosciences LLC has approximately 1 employees.
Hemera Biosciences LLC has completed 1 funding round, raising a total of $1.30M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Hemera Biosciences LLC include Beacon Therapeutics, Adverum Biotechnologies, Catalyst Biosciences, Opus Genetics, GelMEDIX. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hemera Biosciences LLC and Beacon Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Hemera Biosciences LLC and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy